MAPT and Alzheimer disease: MAPT mRNA expression levels were significantly higher in AD subjects treated with AChEIs (n = 25) than in subjects not treated with AChEIs (n = 25) (unmedicated 0.83 ± 0.33 vs. medicated 1.12 ± 0.59, P value = 0.049; Figure 3).